Compare Eli Lilly And Co (LLY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while Direxion Daily TSLA Bull 2X Shares trades at $10.48 (market cap $3.97B). The key difference: Eli Lilly And Co is far larger — about 262× Direxion Daily TSLA Bull 2X Shares's market cap, and Eli Lilly And Co pays a 0.59% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| LLY | TSLL | |
|---|---|---|
Market Cap | $1.04T | $3.97B |
Volume | 3,064,878 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $23.03 |
52-Week Low | $799.57 | $6.74 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.43, up 2.76% with neutral technical signals. The leveraged ETF tracks Tesla's daily performance, showing recent strength tied to Tesla's Cybercab event anticipation. Moving averages indicate bullish momentum while oscillators remain neutral, with RSI suggesting potential overbought conditions at shorter timeframes.
As a leveraged ETF, TSLL carries amplified risk from Tesla's volatility and daily reset mechanics. Recent news highlights both opportunity from Tesla catalysts and structural risks where investors can lose money even when Tesla rises. The ETF's performance depends entirely on Tesla's stock movement and market sentiment toward electric vehicle innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
